Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index; none of the 124 sources its claims cite is checked for support yet.

Acquisition of neurodegenerative features in isogenic OPTN(E50K) human stem cell-derived retinal ganglion cells associated with autophagy disruption and mTORC1 signaling reduction

Open access

Published version of a preprint

Abstract

The ability to derive retinal ganglion cells (RGCs) from human pluripotent stem cells (hPSCs) has led to numerous advances in the field of retinal research, with great potential for the use of hPSC-derived RGCs for studies of human retinal development, in vitro disease modeling, drug discovery, as well as their potential use for cell replacement therapeutics. Of all these possibilities, the use of hPSC-derived RGCs as a human-relevant platform for in vitro disease modeling has received the greatest attention, due to the translational relevance as well as the immediacy with which results may be obtained compared to more complex applications like cell replacement. While several studies to date have focused upon the use of hPSC-derived RGCs with genetic variants associated with glaucoma or other optic neuropathies, many of these have largely described cellular phenotypes with only limited advancement into exploring dysfunctional cellular pathways as a consequence of the disease-associated gene variants. Thus, to further advance this field of research, in the current study we leveraged an isogenic hPSC model with a glaucoma-associated mutation in the Optineurin (OPTN) protein, which plays a prominent role in autophagy. We identified an impairment of autophagic-lysosomal degradation and decreased mTORC1 signaling via activation of the stress sensor AMPK, along with subsequent neurodegeneration in OPTN(E50K) RGCs differentiated from hPSCs, and have further validated some of these findings in a mouse model of ocular hypertension. Pharmacological inhibition of mTORC1 in hPSC-derived RGCs recapitulated disease-related neurodegenerative phenotypes in otherwise healthy RGCs, while the mTOR-independent induction of autophagy reduced protein accumulation and restored neurite outgrowth in diseased OPTN(E50K) RGCs. Taken together, these results highlighted that autophagy disruption resulted in increased autophagic demand which was associated with downregulated signaling through mTORC1, contributing to the degeneration of RGCs.

Overview

CoChat Summary

TL;DR

In isogenic hPSC-derived RGCs, the glaucoma-associated OPTN(E50K) mutation impaired autophagic-lysosomal degradation, reduced mTORC1 signaling via AMPK activation, and produced selective neurodegenerative phenotypes. mTOR-independent autophagy induction with trehalose rescued neurite outgrowth and reduced protein accumulation, whereas mTORC1 inhibition reproduced degenerative phenotypes in healthy RGCs.

Key findings

  • OPTN(E50K) RGCs had unchanged OPTN mRNA but 41.1 ± 5.2% lower OPTN protein and 28.1 ± 4.3% higher p62; proteomics identified 154 downregulated and 178 upregulated proteins, including altered autophagy- and ubiquitination-associated proteins.
  • Autophagic-lysosomal degradation was impaired: LC3-OPTN colocalization was 10.7 ± 1.2% in wild-type vs 5.1 ± 0.6% in OPTN(E50K) RGCs; LC3-II, LAMP1, and LC3-II/I were increased (p = 0.016, p = 0.0018, p = 0.039), and LC3-RFP-GFP showed more autophagosomes in OPTN(E50K) RGCs (35.8 ± 2.5% vs 25.5 ± 2.8% wild-type, p = 0.0075).
  • mTORC1 signaling was reduced: pS6Ser240/244 decreased (p = 0.0057), pAKTSer473 was unchanged (p = 0.854), and pAMPKThr172 increased (p = 0.0027); in the mouse ocular hypertension model, pS6 decreased (p = 0.011) and LC3-II, LAMP1, and LC3-II/I increased (p = 0.034, p = 0.0004, p = 0.042).
  • OPTN(E50K) caused RGC-selective neurite deficits, while cortical neurons showed no significant differences; mTOR inhibitor KU0063794 caused dose-dependent neurite shortening in healthy RGCs, and trehalose reduced OPTN puncta, reduced LC3-II, sustained pS6, and protected neurites in OPTN(E50K) RGCs.

Methods

  • Isogenic hPSC model: H7 hESC and patient iPSC lines with OPTN(E50K) or CRISPR-corrected controls, with or without a BRN3b-tdTomato-Thy1.2 reporter; retinal organoids were differentiated, RGCs purified by CD90.2/Thy1.2 MACS, and matured up to 4 weeks; hPSC-derived cortical neurons were used for comparison.
  • Mouse glaucoma model: adult female C57BL/6 mice (2–3 months, 20.3–25.1 g) received unilateral magnetic microbead anterior chamber injection to elevate intraocular pressure, with sham controls; retinas were analyzed 2 weeks after.
  • Main assays: qPCR, immunoblotting, immunostaining, LC3-RFP-GFP autophagosome maturation assay, neurite tracing/Sholl analysis, TMT LC-MS/MS proteomics, and glucose uptake; statistics used t-test or ANOVA with Tukey post hoc, p < 0.05.

Limitations

  • Stated: mouse autophagy findings used whole retina rather than purified RGCs, which may explain the less robust disruption compared with human hPSC-RGCs; the lack of OPTN protein difference in ocular hypertensive vs control mouse retinas could be due to analysis of total retinal protein rather than RGC content.
  • Stated: whether decreased LC3 recruitment by OPTN directly causes autophagy defects or is compensated by other autophagy receptors remains undetermined, and whether AMPK regulates autophagy directly or indirectly through mTORC1 suppression still needs determination; the study also did not compare RGCs with other projection neurons such as motor neurons.
  • Evident from the text: hPSC-derived RGCs are described as a somewhat immature developmental stage, so findings may not fully capture adult human RGC biology; several experiments rely on technical replicates with small biological n (e.g., n = 3 biological replicates), which may limit generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s40478-024-01872-2

Cites

109 of 109 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 The glaucoma associated OPTN(E50K) mutation alters endogenous protein modification and aggregates in hPSC-RGCs. A Real-time RT-PCR quantification of OPTN mRNA levels (n = 3 for each WT and E50K; t-test, p = 0.181). B–C Western blot and the relative protein expression of OPTN and p62 to β-actin in hPSC-RGCs (n = 5 for each WT and E50K; t-test, OPTN ****p < 0.0001, p62 ***p = 0.0002). D Proteomics analysis demonstrated changes in the expression of autophagy-associated proteins in OPTN(E50K) hPSC-RGCs. E–F Immunostaining displayed the expression of OPTN puncta in BRN3:tdTomato hPSC-RGCs from WT and E50K under steady state (control) and chloroquine (CQ) treatment. Arrows indicate the OPTN puncta. Scale bar: 10 μm. G–H Quantification of OPTN puncta in hPSC-RGCs. I–J Immunostaining displayed the expression of p62 puncta in BRN3:tdTomato hPSC-RGCs from WT and E50K under control and CQ treatment. K–L Quantification of p62 puncta in hPSC-RGCs. G–H and K–L: n = 3 biological replicates using Ctrl-WT n = 60, Ctrl-E50K n = 60, CQ-WT n = 57 and CQ-E50K n = 48 technical replicates; One-way ANOVA, Tukey post hoc test. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns = not significant, p > 0.05). Data are represented as mean values ± SEM
Fig. 1 The glaucoma associated OPTN(E50K) mutation alters endogenous protein modification and aggregates in hPSC-RGCs. A Real-time RT-PCR quantification of OPTN mRNA levels (n = 3 for each WT and E50K; t-test, p = 0.181). B–C Western blot and the relative protein expression of OPTN and p62 to β-actin in hPSC-RGCs (n = 5 for each WT and E50K; t-test, OPTN ****p < 0.0001, p62 ***p = 0.0002). D Proteomics analysis demonstrated changes in the expression of autophagy-associated proteins in OPTN(E50K) hPSC-RGCs. E–F Immunostaining displayed the expression of OPTN puncta in BRN3:tdTomato hPSC-RGCs from WT and E50K under steady state (control) and chloroquine (CQ) treatment. Arrows indicate the OPTN puncta. Scale bar: 10 μm. G–H Quantification of OPTN puncta in hPSC-RGCs. I–J Immunostaining displayed the expression of p62 puncta in BRN3:tdTomato hPSC-RGCs from WT and E50K under control and CQ treatment. K–L Quantification of p62 puncta in hPSC-RGCs. G–H and K–L: n = 3 biological replicates using Ctrl-WT n = 60, Ctrl-E50K n = 60, CQ-WT n = 57 and CQ-E50K n = 48 technical replicates; One-way ANOVA, Tukey post hoc test. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns = not significant, p > 0.05). Data are represented as mean values ± SEMCC BY-NC-ND · PubMed Central
Fig. 2 OPTN(E50K) hPSC-RGCs displays autophagosome accumulation and impairs autophagic-lysosomal degradation. A–I Analysis of protein colocalization between OPTN and LC3 in hPSC-RGCs (n = 3 biological replicates using WT (n = 36) and E50K (n = 40); t-test, ****p < 0.0001). Yellow arrows label the colocalization between OPTN and LC3 puncta, and white arrows represented that the LC3 puncta did not colocalize with OPTN. Scale bar: 10 μm. J–L Western blot and subsequent analysis of relative protein expression demonstrated increased LC3-II, LAMP1 and autophagic flux (LC3-II to LC3-I ratio) in OPTN(E50K) hPSC-RGCs (n = 6 for each WT and E50K; t-test, LC3-I p = 0.41, LC3-II *p = 0.016, LAMP1 **p = 0.0018, LC3-II/I *p = 0.039). M Schematic of LC3-RFP-GFP probe paradigm. N–V Using LC3-RFP-GFP probe showed the accumulation of autophagosome (RFP + GFP +) in OPTN(E50K) hPSC-RGCs (n = 3 biological replicates using WT n = 44 and E50K n = 45 technical replicates; t-test, **p = 0.0075). Scale bar: 10 μm in A, also refers to E; 5 μm in B, also refers to C, D, F–H. Data are all represented as mean values ± SEM
Fig. 2 OPTN(E50K) hPSC-RGCs displays autophagosome accumulation and impairs autophagic-lysosomal degradation. A–I Analysis of protein colocalization between OPTN and LC3 in hPSC-RGCs (n = 3 biological replicates using WT (n = 36) and E50K (n = 40); t-test, ****p < 0.0001). Yellow arrows label the colocalization between OPTN and LC3 puncta, and white arrows represented that the LC3 puncta did not colocalize with OPTN. Scale bar: 10 μm. J–L Western blot and subsequent analysis of relative protein expression demonstrated increased LC3-II, LAMP1 and autophagic flux (LC3-II to LC3-I ratio) in OPTN(E50K) hPSC-RGCs (n = 6 for each WT and E50K; t-test, LC3-I p = 0.41, LC3-II *p = 0.016, LAMP1 **p = 0.0018, LC3-II/I *p = 0.039). M Schematic of LC3-RFP-GFP probe paradigm. N–V Using LC3-RFP-GFP probe showed the accumulation of autophagosome (RFP + GFP +) in OPTN(E50K) hPSC-RGCs (n = 3 biological replicates using WT n = 44 and E50K n = 45 technical replicates; t-test, **p = 0.0075). Scale bar: 10 μm in A, also refers to E; 5 μm in B, also refers to C, D, F–H. Data are all represented as mean values ± SEMCC BY-NC-ND · PubMed Central
Fig. 3 Attenuation of mTORC1 signaling in OPTN(E50K) hPSC-RGCs. A–F Western blot and the relative protein expression of pS6Ser240/244, pAKTSer473 and pAMPKThr172 to its total protein, respectively, in hPSC-RGCs (n = 6 for each WT and E50K; t-test, pS6Ser240/244 **p = 0.0057; pAKTSer473 ns = not significant, p = 0.854; pAMPKThr172 **p = 0.0027). G–M Immunostaining and quantification of pS6Ser240/244 intensity revealed that a subset of RGCs with the OPTN(E50K) mutation reduced the expression of pS6Ser240/244 (n = 3 biological replicates using WT n = 96 and E50K n = 96 technical replicates; t-test, ***p = 0.0009). Arrows indicate RGCs that have reduced expression of pS6Ser240/244. N RNA-seq analyses demonstrated a significant reduction in some mTOR-associated genes. Scale bar: 25 μm. Data are all represented as mean values ± SEM
Fig. 3 Attenuation of mTORC1 signaling in OPTN(E50K) hPSC-RGCs. A–F Western blot and the relative protein expression of pS6Ser240/244, pAKTSer473 and pAMPKThr172 to its total protein, respectively, in hPSC-RGCs (n = 6 for each WT and E50K; t-test, pS6Ser240/244 **p = 0.0057; pAKTSer473 ns = not significant, p = 0.854; pAMPKThr172 **p = 0.0027). G–M Immunostaining and quantification of pS6Ser240/244 intensity revealed that a subset of RGCs with the OPTN(E50K) mutation reduced the expression of pS6Ser240/244 (n = 3 biological replicates using WT n = 96 and E50K n = 96 technical replicates; t-test, ***p = 0.0009). Arrows indicate RGCs that have reduced expression of pS6Ser240/244. N RNA-seq analyses demonstrated a significant reduction in some mTOR-associated genes. Scale bar: 25 μm. Data are all represented as mean values ± SEMCC BY-NC-ND · PubMed Central
Fig. 4 Glaucoma RGCs subjected to ocular hypertensive stress demonstrate autophagy deficits. A, B Immunostaining labeled the level of the mTORC1 effector pS6Ser240/244 and exhibited robust activity in the ganglion cell layer (GCL), co-labeled with RBPMS in B, and inner nuclear layer (INL) in control mouse retina. Scale bar: 25 μm. C–E Under ocular hypertension, immunostaining and associated quantification demonstrated that the level of pS6Ser240/244 decreased in mouse RGCs (n = 3 mice/group, 2 images/mice; t-test, *p = 0.011). F–H Western blot verified changes in protein expression of LC3-I, LC3-II, LAMP1, and LC3-II/I ratio in control or glaucoma mouse retinas with ocular hypertension (OHT) (n = 6 for each control and OHT; t-test, LC3-I p = 0.122, LC3-II *p = 0.034, LAMP1 ***p = 0.0004, LC3-II/I *p = 0.042). I–L Immunostaining displayed the elevation of LC3 and LAMP1 in RBPMS-expressing RGCs after ocular hypertension. Scale bar: 25 μm. Data are all represented as mean values ± SEM
Fig. 4 Glaucoma RGCs subjected to ocular hypertensive stress demonstrate autophagy deficits. A, B Immunostaining labeled the level of the mTORC1 effector pS6Ser240/244 and exhibited robust activity in the ganglion cell layer (GCL), co-labeled with RBPMS in B, and inner nuclear layer (INL) in control mouse retina. Scale bar: 25 μm. C–E Under ocular hypertension, immunostaining and associated quantification demonstrated that the level of pS6Ser240/244 decreased in mouse RGCs (n = 3 mice/group, 2 images/mice; t-test, *p = 0.011). F–H Western blot verified changes in protein expression of LC3-I, LC3-II, LAMP1, and LC3-II/I ratio in control or glaucoma mouse retinas with ocular hypertension (OHT) (n = 6 for each control and OHT; t-test, LC3-I p = 0.122, LC3-II *p = 0.034, LAMP1 ***p = 0.0004, LC3-II/I *p = 0.042). I–L Immunostaining displayed the elevation of LC3 and LAMP1 in RBPMS-expressing RGCs after ocular hypertension. Scale bar: 25 μm. Data are all represented as mean values ± SEMCC BY-NC-ND · PubMed Central
Fig. 5 Selective degeneration of RGCs with the OPTN(E50K) mutation. A Immunostaining to characterize wild-type and OPTN(E50K) RGCs. Scale bar: 25 μm. B Representative neurite tracing of wild-type and OPTN(E50K) RGCs after 4 weeks of purification. Scale bar: 150 μm. C Sholl analysis revealed the neurite complexity in wild-type and OPTN(E50K) RGCs (n = 3 biological replicates using WT n = 15 and E50K n = 17 technical replicates; t-test, ****p < 0.0001). D Immunostaining to characterize wild-type and OPTN(E50K) cortical neurons. E Representative neurite tracing of wild-type and OPTN(E50K) cortical neurons 4 weeks after purification. Scale bar: 150 μm. F Sholl analysis revealed similar neurite complexity in wild-type and OPTN(E50K) cortical neurons (n = 3 biological replicates using WT n = 16 and E50K n = 17 technical replicates; t-test, ns = not significant, p = 0.37). G–I Quantitative analysis of neurite parameters displayed neurite deficits in OPTN(E50K) RGCs based upon measurements of soma area (n = 3 biological replicates using RGC-WT n = 101, RGC-E50K n = 112, cortical-WT n = 68, and cortical-E50K n = 66 technical replicates; t-test, RGC: *** p = 0.0003; cortical: ns = not significant, p = 0.811) G, number of primary neurites (n = 3 biological replicates using RGC-WT n = 15, RGC-E50K n = 17, cortical-WT n = 16, and cortical-E50K n = 17 technical replicates; t-test, RGC: ** p = 0.004; cortical: ns = not significant, p = 0.626) H and total neurite length (n = 3 biological replicates using RGC-WT n = 15, RGC-E50K n = 17, cortical-WT n = 16, and cortical-E50K n = 17 technical replicates; t-test, RGC: **** p < 0.0001; cortical: ns = not significant, p = 0.575) I, but not in OPTN(E50K) cortical neurons when compared with wild-type. J–M Western blot and quantified relative protein expression demonstrated that the OPTN(E50K) mutation altered LC3-II only in RGCs (n = 3 for each WT and E50K from RGC or cortical neurons; One-way ANOVA, Tukey post hoc test. ***p < 0.001, **p < 0.01, *p < 0.05, ns = not significant, p > 0.05). N–U Immunostaining displayed the expression of OPTN puncta in hPSC-derived cortical neurons from WT and E50K under steady state (control) N–Q and chloroquine (CQ) treatment R–U. Scale bar: 10 μm. V, W Quantification of OPTN puncta in hPSC-derived cortical neurons (n = 3 biological replicates using Ctrl-WT n = 39, Ctrl-E50K n = 34, CQ-WT n = 37 and CQ-E50K n = 37 technical replicates; One-way ANOVA, Tukey post hoc test. ****p < 0.0001, ***p < 0.001, *p < 0.05, ns = not significant, p > 0.05). Data are all represented as mean values ± SEM
Fig. 5 Selective degeneration of RGCs with the OPTN(E50K) mutation. A Immunostaining to characterize wild-type and OPTN(E50K) RGCs. Scale bar: 25 μm. B Representative neurite tracing of wild-type and OPTN(E50K) RGCs after 4 weeks of purification. Scale bar: 150 μm. C Sholl analysis revealed the neurite complexity in wild-type and OPTN(E50K) RGCs (n = 3 biological replicates using WT n = 15 and E50K n = 17 technical replicates; t-test, ****p < 0.0001). D Immunostaining to characterize wild-type and OPTN(E50K) cortical neurons. E Representative neurite tracing of wild-type and OPTN(E50K) cortical neurons 4 weeks after purification. Scale bar: 150 μm. F Sholl analysis revealed similar neurite complexity in wild-type and OPTN(E50K) cortical neurons (n = 3 biological replicates using WT n = 16 and E50K n = 17 technical replicates; t-test, ns = not significant, p = 0.37). G–I Quantitative analysis of neurite parameters displayed neurite deficits in OPTN(E50K) RGCs based upon measurements of soma area (n = 3 biological replicates using RGC-WT n = 101, RGC-E50K n = 112, cortical-WT n = 68, and cortical-E50K n = 66 technical replicates; t-test, RGC: *** p = 0.0003; cortical: ns = not significant, p = 0.811) G, number of primary neurites (n = 3 biological replicates using RGC-WT n = 15, RGC-E50K n = 17, cortical-WT n = 16, and cortical-E50K n = 17 technical replicates; t-test, RGC: ** p = 0.004; cortical: ns = not significant, p = 0.626) H and total neurite length (n = 3 biological replicates using RGC-WT n = 15, RGC-E50K n = 17, cortical-WT n = 16, and cortical-E50K n = 17 technical replicates; t-test, RGC: **** p < 0.0001; cortical: ns = not significant, p = 0.575) I, but not in OPTN(E50K) cortical neurons when compared with wild-type. J–M Western blot and quantified relative protein expression demonstrated that the OPTN(E50K) mutation altered LC3-II only in RGCs (n = 3 for each WT and E50K from RGC or cortical neurons; One-way ANOVA, Tukey post hoc test. ***p < 0.001, **p < 0.01, *p < 0.05, ns = not significant, p > 0.05). N–U Immunostaining displayed the expression of OPTN puncta in hPSC-derived cortical neurons from WT and E50K under steady state (control) N–Q and chloroquine (CQ) treatment R–U. Scale bar: 10 μm. V, W Quantification of OPTN puncta in hPSC-derived cortical neurons (n = 3 biological replicates using Ctrl-WT n = 39, Ctrl-E50K n = 34, CQ-WT n = 37 and CQ-E50K n = 37 technical replicates; One-way ANOVA, Tukey post hoc test. ****p < 0.0001, ***p < 0.001, *p < 0.05, ns = not significant, p > 0.05). Data are all represented as mean values ± SEMCC BY-NC-ND · PubMed Central
Fig. 6 mTOR inhibition contributed to neurite shortening in hPSC-derived RGCs. A Schematic timeline of mTOR inhibitor treatment and methods for neurite analyses. B–C Quantification and immunostaining revealed that pS6Ser240/244 intensity was dose-dependent in response to mTOR inhibition in hPSC-RGCs (n = 3 biological replicates using vehicle (DMSO) n = 162, 10 nM n = 143, 100 nM n = 128, 500 nM n = 121, and 1 μM n = 133 technical replicates; One-way ANOVA, Tukey post hoc test. ****p < 0.0001 for each KU0063794 treatment group compared to vehicle treatment). Scale bar: 25 μm. D–G Western blot and quantification of the relative protein expression displayed a decrease of mTOR signaling and induction of autophagy when mTOR was inhibited by KU0063794 treatment in hPSC-RGCs (n = 3 for each vehicle (DMSO) and 1 μM of KU0063794 treatment, t-test, pS6Ser240/244 ****p < 0.0001, pAKTSer473 **p = 0.0033, pAMPKThr172 **p = 0.0292, LC3-I ***p = 0.0006, LC3-II **p = 0.001, LC3-II/I p = 0.838, LAMP1 p = 0.23). H Representative neurite tracings of vehicle and KU0063794 treatment in hPSC-RGCs. Scale bar: 200 μm. I–L Quantitative analysis of neurite parameters displayed neurite deficits and decreased neurite complexity following mTOR inhibition in hPSC-RGCs as measured by their soma area (n = 3 biological replicates using vehicle n = 107, 10 nM n = 109, 100 nM n = 97, 500 nM n = 107, and 1 μM n = 93 technical replicates; One-way ANOVA, Tukey post hoc test. ****p < 0.0001, ***p < 0.001) I, number of primary neurites (n = 3 biological replicates using vehicle n = 16, 10 nM n = 16, 100 nM n = 16, 500 nM n = 17, and 1 μM n = 15 technical replicates; One-way ANOVA, Tukey post hoc test. ****p < 0.0001, ***p < 0.001, ns = not significant, p > 0.05) J, total neurite length (n = 3 biological replicates using vehicle n = 16, 10 nM n = 16, 100 nM n = 16, 500 nM n = 17, and 1 μM n = 15 technical replicates; One-way ANOVA, Tukey post hoc test. ****p < 0.0001, **p < 0.01, ns = not significant, p > 0.05) K, and Sholl analysis (n = 3 biological replicates using vehicle n = 16, and 1 μM n = 15 technical replicates; t-test, ****p < 0.0001) L. Data are all represented as mean values ± SEM
Fig. 6 mTOR inhibition contributed to neurite shortening in hPSC-derived RGCs. A Schematic timeline of mTOR inhibitor treatment and methods for neurite analyses. B–C Quantification and immunostaining revealed that pS6Ser240/244 intensity was dose-dependent in response to mTOR inhibition in hPSC-RGCs (n = 3 biological replicates using vehicle (DMSO) n = 162, 10 nM n = 143, 100 nM n = 128, 500 nM n = 121, and 1 μM n = 133 technical replicates; One-way ANOVA, Tukey post hoc test. ****p < 0.0001 for each KU0063794 treatment group compared to vehicle treatment). Scale bar: 25 μm. D–G Western blot and quantification of the relative protein expression displayed a decrease of mTOR signaling and induction of autophagy when mTOR was inhibited by KU0063794 treatment in hPSC-RGCs (n = 3 for each vehicle (DMSO) and 1 μM of KU0063794 treatment, t-test, pS6Ser240/244 ****p < 0.0001, pAKTSer473 **p = 0.0033, pAMPKThr172 **p = 0.0292, LC3-I ***p = 0.0006, LC3-II **p = 0.001, LC3-II/I p = 0.838, LAMP1 p = 0.23). H Representative neurite tracings of vehicle and KU0063794 treatment in hPSC-RGCs. Scale bar: 200 μm. I–L Quantitative analysis of neurite parameters displayed neurite deficits and decreased neurite complexity following mTOR inhibition in hPSC-RGCs as measured by their soma area (n = 3 biological replicates using vehicle n = 107, 10 nM n = 109, 100 nM n = 97, 500 nM n = 107, and 1 μM n = 93 technical replicates; One-way ANOVA, Tukey post hoc test. ****p < 0.0001, ***p < 0.001) I, number of primary neurites (n = 3 biological replicates using vehicle n = 16, 10 nM n = 16, 100 nM n = 16, 500 nM n = 17, and 1 μM n = 15 technical replicates; One-way ANOVA, Tukey post hoc test. ****p < 0.0001, ***p < 0.001, ns = not significant, p > 0.05) J, total neurite length (n = 3 biological replicates using vehicle n = 16, 10 nM n = 16, 100 nM n = 16, 500 nM n = 17, and 1 μM n = 15 technical replicates; One-way ANOVA, Tukey post hoc test. ****p < 0.0001, **p < 0.01, ns = not significant, p > 0.05) K, and Sholl analysis (n = 3 biological replicates using vehicle n = 16, and 1 μM n = 15 technical replicates; t-test, ****p < 0.0001) L. Data are all represented as mean values ± SEMCC BY-NC-ND · PubMed Central
Fig. 7 mTOR-independent activator prevents neurite retraction and clears protein accumulation in OPTN(E50K) hPSC-RGCs. A Representative images of soma area in wild-type, OPTN(E50K), and trehalose-treated OPTN(E50K) hPSC-RGCs. Scale bar 25 μm. B–D Representative neurite tracing images of wild-type, OPTN(E50K), and trehalose-treated OPTN(E50K) hPSC-RGCs. Scale bar: 200 μm. E–H Quantitative analysis of neurite parameters demonstrated protection of neurites in OPTN(E50K) hPSC-RGCs after trehalose treatment for 2 weeks, as measured by the soma area (n = 3 biological replicates using WT n = 30, E50K n = 30, and E50K-trehalose n = 30 technical replicates, One-way ANOVA, Tukey post hoc test. ****p < 0.0001, ns = not significant, p > 0.05) E, number of primary neurites (n = 3 biological replicates using WT n = 15, E50K n = 15, and E50K-trehalose n = 15 technical replicates; One-way ANOVA, Tukey post hoc test. ****p < 0.0001, ***p < 0.001, ns = not significant, p > 0.05) F, total neurite length (n = 3 biological replicates using WT n = 15, E50K n = 15, and E50K-trehalose n = 15 technical replicates; One-way ANOVA, Tukey post hoc test. **p < 0.01, ns = not significant, p > 0.05) G, and Sholl analysis (n = 3 biological replicates using WT n = 15, E50K n = 15, and E50K-trehalose n = 15 technical replicates; One-way ANOVA, Tukey post hoc test. WT vs E50K: **p = 0.0095; WT vs E50K(trehalose): ns = not significant, p = 0.81; E50K vs E50K(trehalose): **p = 0.0012) H. I–N Immunostaining displayed the decrease of OPTN puncta in OPTN(E50K) hPSC-RGCs after trehalose treatment. Scale bar: 10 μm. O, P Quantification of OPTN puncta in hPSC-RGCs (n = 3 biological replicates using WT n = 51, E50K n = 60, and E50K-trehalose n = 61 technical replicates; One-way ANOVA, Tukey post hoc test. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns = not significant, p > 0.05). Q–T Western blot and the relative protein expression demonstrated the recovery of changes to LC3-II and pS6Ser240/244 expression in OPTN(E50K) hPSC-RGCs after trehalose treatment. (n = 5 for each WT, E50K, and E50K with trehalose treatment; One-way ANOVA, Tukey post hoc test. LC3-I: WT vs E50K: p = 0.41, WT vs E50K(trehalose): p = 0.91, E50K vs E50K(trehalose): p = 0.23. LC3-II: WT vs E50K: p = 0.03, WT vs E50K(trehalose): p = 0.99, E50K vs E50K(trehalose): p = 0.03. pS6: WT vs E50K: p = 0.048, WT vs E50K(trehalose): p = 0.95, E50K vs E50K(trehalose): p = 0.029.). Data are all represented as mean values ± SEM
Fig. 7 mTOR-independent activator prevents neurite retraction and clears protein accumulation in OPTN(E50K) hPSC-RGCs. A Representative images of soma area in wild-type, OPTN(E50K), and trehalose-treated OPTN(E50K) hPSC-RGCs. Scale bar 25 μm. B–D Representative neurite tracing images of wild-type, OPTN(E50K), and trehalose-treated OPTN(E50K) hPSC-RGCs. Scale bar: 200 μm. E–H Quantitative analysis of neurite parameters demonstrated protection of neurites in OPTN(E50K) hPSC-RGCs after trehalose treatment for 2 weeks, as measured by the soma area (n = 3 biological replicates using WT n = 30, E50K n = 30, and E50K-trehalose n = 30 technical replicates, One-way ANOVA, Tukey post hoc test. ****p < 0.0001, ns = not significant, p > 0.05) E, number of primary neurites (n = 3 biological replicates using WT n = 15, E50K n = 15, and E50K-trehalose n = 15 technical replicates; One-way ANOVA, Tukey post hoc test. ****p < 0.0001, ***p < 0.001, ns = not significant, p > 0.05) F, total neurite length (n = 3 biological replicates using WT n = 15, E50K n = 15, and E50K-trehalose n = 15 technical replicates; One-way ANOVA, Tukey post hoc test. **p < 0.01, ns = not significant, p > 0.05) G, and Sholl analysis (n = 3 biological replicates using WT n = 15, E50K n = 15, and E50K-trehalose n = 15 technical replicates; One-way ANOVA, Tukey post hoc test. WT vs E50K: **p = 0.0095; WT vs E50K(trehalose): ns = not significant, p = 0.81; E50K vs E50K(trehalose): **p = 0.0012) H. I–N Immunostaining displayed the decrease of OPTN puncta in OPTN(E50K) hPSC-RGCs after trehalose treatment. Scale bar: 10 μm. O, P Quantification of OPTN puncta in hPSC-RGCs (n = 3 biological replicates using WT n = 51, E50K n = 60, and E50K-trehalose n = 61 technical replicates; One-way ANOVA, Tukey post hoc test. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns = not significant, p > 0.05). Q–T Western blot and the relative protein expression demonstrated the recovery of changes to LC3-II and pS6Ser240/244 expression in OPTN(E50K) hPSC-RGCs after trehalose treatment. (n = 5 for each WT, E50K, and E50K with trehalose treatment; One-way ANOVA, Tukey post hoc test. LC3-I: WT vs E50K: p = 0.41, WT vs E50K(trehalose): p = 0.91, E50K vs E50K(trehalose): p = 0.23. LC3-II: WT vs E50K: p = 0.03, WT vs E50K(trehalose): p = 0.99, E50K vs E50K(trehalose): p = 0.03. pS6: WT vs E50K: p = 0.048, WT vs E50K(trehalose): p = 0.95, E50K vs E50K(trehalose): p = 0.029.). Data are all represented as mean values ± SEMCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

0 Valid · 1 Not valid · 64 Not checked · 143 Own results and interpretations

135 more claims

Create a free account to see all 208 claims and to verify the 124 references still open.

See all claims — free account
  • It may state two separate claims as one. 44
  • Probably not a substantial claim. 29
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Cited by

See all 19

Metadata

Authors
Huang, K.-C., Gomes, C., Shiga, Y., Belforte, N., VanderWall, K. B., Lavekar, S. S., Fligor, C. M., Harkin, J., Hetzer, S. M., Patil, S. V., Di Polo, A., & Meyer, J. S.
Affiliations
  • Indiana University School of Medicine (US)
  • Indiana University Indianapolis (US)
  • Université de Montréal (CA)
Corresponding author
Meyer, Jason S.
Venue
Acta Neuropathologica Communications
Published
2024-10-18
Volume
12
Issue
1
Pages
164-164
ISSN
2051-5960 (ISSN-L)
OpenAlex
W4403513715
Cited by
19
References
109
Citations by year
2026: 9 · 2025: 6 · 2024: 3
FWCI
5.92
Type
journal article
Language
en
Open access
Licence
Locations
  • Acta Neuropathologica Communications (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by)
  • PubMed Central (submittedVersion, cc-by)
  • PubMed (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion, cc-by-nc-nd)
Funders
  • National Eye Institute (R01EY033022, U24EY033269, R01EY030838)
  • BrightFocus Foundation (G2020369, G2022003F)
  • Glaucoma Research Foundation
  • Indiana State Department of Health (26343)
  • Fonds de Recherche du Québec - Santé (276181)
  • Canadian Institutes of Health Research (458569)
  • Gilbert Family Foundation (923016)
Topics
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
Keywords
optineurin, retinal ganglion cells, human pluripotent stem cells, glaucoma, neurodegeneration, autophagy, mTORC1 signaling, AMPK, ocular hypertension, neurite outgrowth, protein accumulation
MeSH terms
Mechanistic Target of Rapamycin Complex 1, Animals, Autophagy, Humans, Retinal Ganglion Cells, Signal Transduction, Cell Cycle Proteins, Membrane Transport Proteins, Pluripotent Stem Cells, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.